BIWEEKLY COMBINATION CHEMOTHERAPY OF DOCETAXEL, IRINOTECAN AND CISPLATIN AS SECOND-LINE TREATMENT FOR ADVANCED GASTRIC CANCER

被引：0
|
作者：
Denda, T. [1 ]
Sudo, K. [1 ]
Nakamura, K. [1 ]
Hara, T. [1 ]
Yamaguchi, T. [1 ]
机构：
[1] Chiba Canc Ctr, Chiba 2608717, Japan
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：174 / 174
页数：1
相关论文
共 50 条
  • [21] Efficacy and Safety of Biweekly Docetaxel in Combination with Nedaplatin as Second-line Chemotherapy for Unresectable or Recurrent Esophageal Cancer
    Kanekiyo, Shinsuke
    Takeda, Shigeru
    Nakajima, Masao
    Nishiyama, Mitsuo
    Kitahara, Masahiro
    Shindou, Yoshitaro
    Michihisa, Iida
    Abe, Toshihiro
    Yoshino, Shigefumi
    Hazama, Shoichi
    Nagano, Hiroaki
    ANTICANCER RESEARCH, 2016, 36 (04) : 1923 - 1927
  • [22] Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer
    Takahari, Daisuke
    Shimada, Yasuhiro
    Takeshita, Shigeyuki
    Nishitani, Hitoshi
    Takashima, Atsuo
    Okita, Natsuko
    Hirashima, Yoshinori
    Kato, Ken
    Hamaguchi, Tetsuya
    Yamada, Yasuhide
    Shirao, Kuniaki
    GASTRIC CANCER, 2010, 13 (03) : 186 - 190
  • [23] Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer
    Daisuke Takahari
    Yasuhiro Shimada
    Shigeyuki Takeshita
    Hitoshi Nishitani
    Atsuo Takashima
    Natsuko Okita
    Yoshinori Hirashima
    Ken Kato
    Tetsuya Hamaguchi
    Yasuhide Yamada
    Kuniaki Shirao
    Gastric Cancer, 2010, 13 : 186 - 190
  • [24] Irinotecan Plus Mitomycin C as Second-Line Chemotherapy for Advanced Gastric Cancer Resistant to Fluoropyrimidine and Cisplatin: A Retrospective Study
    Ogawa, Kohei
    Hosokawa, Ayumu
    Ueda, Akira
    Saito, Seiko
    Mihara, Hiroshi
    Ando, Takayuki
    Kajiura, Shinya
    Terada, Mitsuhiro
    Tsukioka, Yuji
    Horikawa, Naoki
    Kobayashi, Takashi
    Note, Masayuki
    Sawasaki, Kunihiro
    Fukuoka, Junya
    Sugiyama, Toshiro
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2012, 2012
  • [25] Phase II study on the combination of irinotecan plus cisplatin as a second-line therapy in patients with advanced or recurrent gastric cancer
    Rino, Yasushi
    Yukawa, Norio
    Sato, Tsutomu
    Oshima, Takashi
    Tanabe, Hiroyasu
    Yamamoto, Yuji
    Matsukawa, Hiroshi
    Shiraishi, Ryuji
    Imada, Toshio
    Masuda, Munetaka
    MOLECULAR AND CLINICAL ONCOLOGY, 2013, 1 (04) : 749 - 752
  • [26] Single-agent irinotecan as second-line treatment for advanced gastric cancer
    Kanat, O
    Evrensel, T
    Manavoglu, O
    Demiray, M
    Kurt, E
    Gonullu, G
    Kiyici, M
    Arslan, M
    TUMORI JOURNAL, 2003, 89 (04): : 405 - 407
  • [27] A randomized trial of FOLFIRI versus docetaxel and cisplatin as a second-line chemotherapy after failure of first-line chemotherapy in advanced gastric cancer
    Kil, Lee Sang
    Seok, Moon Hee
    Eun, Kim Sung
    Seok, Jang Jin
    Young, Cho Joo
    Sun, Kim Eun
    Hyung, Lee Si
    Chul, Park Jun
    Kang, Lee Yong
    ANNALS OF ONCOLOGY, 2017, 28
  • [28] DOCETAXEL-GEMCITABINE AS SECOND-LINE TREATMENT FOR PATIENTS WITH ADVANCED GASTRIC CANCER
    D'Alessio, Andrea
    Amato, Maria Grazia
    Resta, Davide
    Sbarufatti, Antonio
    Tacchini, Laura
    Venturi, Cristina
    Visacarra, Cecilia
    ANNALS OF ONCOLOGY, 2009, 20
  • [29] Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: A randomised phase III trial (TCOG GI-0801/BIRIP trial)
    Higuchi, Katsuhiko
    Tanabe, Satoshi
    Shimada, Ken
    Hosaka, Hisashi
    Sasaki, Eisaku
    Nakayama, Norisuke
    Takeda, Yuiti
    Moriwaki, Toshikazu
    Amagai, Kenji
    Sekikawa, Takashi
    Sakuyama, Toshikazu
    Kanda, Tatsuo
    Sasaki, Tohru
    Azuma, Mizutomo
    Takahashi, Fumiaki
    Takeuchi, Masahiro
    Koizumi, Wasaburo
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (08) : 1437 - 1445
  • [30] Efficacy of sequential use of docetaxel / 5-fluorouracil / cisplatin as first-line, and irinotecan/levofolinate/5-fluorouracil as second-line chemotherapy for advanced gastric cancer
    Sugiyama, K.
    Ishikawa, A.
    Sato, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345